These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17687166)

  • 41. Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Dizon DS
    Gynecol Oncol; 2017 Feb; 144(2):241-242. PubMed ID: 28062117
    [No Abstract]   [Full Text] [Related]  

  • 42. Prescribing patterns of surgical oncologists: are we surgeons, oncologists, or both? Results of a society of surgical oncology survey.
    Balch CM
    Ann Surg Oncol; 2007 Oct; 14(10):2685-6. PubMed ID: 17786520
    [No Abstract]   [Full Text] [Related]  

  • 43. The medical-surgical nurse's guide to ovarian cancer: Part II.
    Bohnenkamp S; LeBaron V; Yoder LH
    Medsurg Nurs; 2007 Oct; 16(5):323-31; quiz 332. PubMed ID: 18072671
    [No Abstract]   [Full Text] [Related]  

  • 44. Oncologists have lost a battle against cancer; biomedicine has not lost the war.
    Mathé G
    Biomed Pharmacother; 1986; 40(10):370-1. PubMed ID: 3580504
    [No Abstract]   [Full Text] [Related]  

  • 45. ESMO 2014: new trends in precision medicine.
    Morere JF; Innominato P
    Target Oncol; 2014 Dec; 9(4):293-4. PubMed ID: 25503266
    [No Abstract]   [Full Text] [Related]  

  • 46. Ovarian cancer staging: does it require a gynecologic oncologist?
    Rich WM
    Gynecol Oncol; 1993 Nov; 51(2):291-2. PubMed ID: 8276312
    [No Abstract]   [Full Text] [Related]  

  • 47. Intraperitoneal chemotherapy in ovarian cancer: an update.
    Runowicz CD
    Cancer J; 2008; 14(1):7-9. PubMed ID: 18303475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
    Patsner B
    Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment for recurrent ovarian cancer].
    Hasegawa K; Torii H; Ooe S; Udagawa Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):230-6. PubMed ID: 19263612
    [No Abstract]   [Full Text] [Related]  

  • 50. Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease.
    Houvras Y; Wirth LJ
    J Clin Oncol; 2011 Jul; 29(19):2616-8. PubMed ID: 21606409
    [No Abstract]   [Full Text] [Related]  

  • 51. The chemoprevention of cancer: directions for the future.
    Daly MB
    Cancer Epidemiol Biomarkers Prev; 1993; 2(6):509-12. PubMed ID: 8268765
    [No Abstract]   [Full Text] [Related]  

  • 52. Ovarian cancer: an analysis of forty-four patients at the National Radiotherapy Centre, Accra--Ghana.
    Vanderpuye V; Yarney J
    West Afr J Med; 2007; 26(2):93-6. PubMed ID: 17939307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Gynecologic cancer].
    Uehara T; Katsumata N
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1488-94. PubMed ID: 18799902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data.
    Markman M
    Oncology; 2006; 71(5-6):309-11. PubMed ID: 17873498
    [No Abstract]   [Full Text] [Related]  

  • 55. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
    Larsen E; Blaakaer J
    Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.
    Bacon M; Kitchener H; Stuart GC; Vermorken JB;
    Int J Gynecol Cancer; 2011 May; 21(4):746-9. PubMed ID: 21543935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting signaling pathways in ovarian cancer.
    Reibenwein J; Krainer M
    Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pros and cons for systemic therapy in recurrent ovarian cancer.
    Oskay-Ozcelik G; Sehouli J
    Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian cancer treatment: what's old is new.
    Health News; 2006 Mar; 12(3):2. PubMed ID: 16535764
    [No Abstract]   [Full Text] [Related]  

  • 60. Complementary and alternative therapy use in gynecologic oncology: implications for clinical practice.
    Richardson MA
    Gynecol Oncol; 2002 Mar; 84(3):360-2. PubMed ID: 11855869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.